De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making

American Journal of Cardiovascular Drugs · Published 2026-06-23 · DOI 10.1007/s40256-026-00806-8

Free full text

Authors (5)

Navid Radfar, Dhir Gala, Harsh Singh, Juan Bello, Joseph Allencherril

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Radfar, N., Gala, D., Singh, H., et al. (2026). De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-026-00806-8

Related articles

• Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Colchicine for Cardiovascular Prevention: Clarity Amidst the Confusion · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Cardiovascular Outcomes Associated with Cholinesterase Inhibitor Use in Individuals at High Cardiovascular Risk · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Redefining Cardiac Sarcoidosis with Advanced Imaging and Therapeutic Strategies · American Journal of Cardiovascular Drugs · 2025 · Same journal
• One-Year Prognostic Differences and Management Strategies between ST-Elevation and Non-ST-Elevation Myocardial Infarction: Insights from the PRAISE Registry · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Cost-Effectiveness and Price Threshold Analysis of Tafolecimab in Chinese Patients with Elevated LDL Cholesterol Despite Statin Therapy · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study · American Journal of Cardiovascular Drugs · 2026 · Same journal
• Disproportionality Analysis of Ivabradine in the US FDA Adverse Event Reporting System: A Real-World Study Across Overall and Indication-Specific Populations · American Journal of Cardiovascular Drugs · 2025 · Same journal
• Mineralocorticoid Receptor Antagonism with Finerenone: A New Era in the Management of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction · American Journal of Cardiovascular Drugs · 2025 · Same journal